

THE FOLLOWING DRUGS WILL BE REVIEWED AT THE
DRUG UTILIZATION REVIEW BOARD MEETING

March 17, 2016

Georgia Department of Community Health

***This list may change at any time. If a supplemental rebate class is not listed below, the class may be reviewed at the June 16th meeting. Any drugs/classes listed below that the DURB is not able to complete during the March 17th meeting will be reviewed at the June 16th meeting. Manufacturers that presented these drugs at the February Manufacturers' Forum will not need to present the drugs again at the May Manufacturers' Forum.**

Information on the Manufacturers' Forum can be found at <http://dch.georgia.gov/manufacturers-forum> and <http://dch.georgia.gov/durb-meeting-information>. Please check back frequently for updates.*

New Drug Reviews

Corlanor

Entresto

Daklinza

Technivie

Zepatier

Praluent

Repatha

Therapeutic Class Reviews

Atypical Antipsychotics, including new drug Rexulti

Antihemophilic Factor VIIIs, including new products Adynovate and Nuwiq

Antihemophilic Factor IXs

Supplemental Rebate Class Reviews

Antihemophilic Products for Von Willebrand Disease

Aminoglycosides for Cystic Fibrosis

Anticoagulants

Anticonvulsants

Antiinflammatory, Antirheumatics

Attention Deficit Hyperactivity Disorder (ADHD) Agents
Biologics, Immunomodulators
Cardiovascular, Angiotensin Receptor Blockers (ARBs)
Cardiovascular, Beta Blockers (BBs)
Dermatologics, Hydrocortisone Solution
Dermatologics, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Dermatologics, Scabicides/Pediculicides
Fibromyalgia Agents
Gastrointestinal, Digestive Enzymes
Gastrointestinal, Inflammatory Bowel Agents
Gastrointestinal, Laxatives
Growth Hormones
Ophthalmics, Adrenergic Agents
Ophthalmics, Antiallergics
Ophthalmics, Antibiotics, Quinolones
Ophthalmics, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Ophthalmics, Prostaglandins
Ophthalmics, Steroid Antibiotic Combinations
Ophthalmics, Steroids
Phosphate Binders

***This list may change at any time. If a supplemental rebate class is not listed below, the class may be reviewed at the June 16th meeting. Any drugs/classes listed below that the DURB is not able to complete during the March 17th meeting will be reviewed at the**

June 16th meeting. Manufacturers that presented these drugs at the February Manufacturers' Forum will not need to present the drugs again at the May Manufacturers' Forum. Information on the Manufacturers' Forum can be found at <http://dch.georgia.gov/manufacturers-forum> and <http://dch.georgia.gov/durb-meeting-information>. Please check back frequently for updates.*